A Phase 2/3 interventional study of Maraviroc (UK-427,857) and optimized background therapy in HIV Infections, sponsored by ViiV Healthcare. Completed at 172 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-05-16.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.
Among the 44 studies testing maraviroc in HIV Infections, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 1st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 9 · Phase 4 15
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 474 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 36 across the 44 interventional studies. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 27th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2004, is one of 3 in phase 2/3, and was the 92nd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing maraviroc in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The purpose of this study is to evaluate the antiretroviral activity of maraviroc (UK-427,857) in HIV infected, treatment experienced patients who are failing their current antiretroviral regimen and infected with R5-tropic virus exclusively. This study will involve more than 100 centers in Europe and Australia to achieve a total randomized subject population of 500 subjects. Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment. This may be extended for an additional year depending on the results at 48 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40 and 48. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 24 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will also be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24 and 48.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc (UK-427,857) · Drug: optimized background therapy
Drug: Maraviroc (UK-427,857) · Drug: optimized background therapy
Drug: optimized background therapy
maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
\[OBT (3-6 drugs based on treatment history and resistance testing)\]
Also known as: Selzentry
maraviroc (UK-427,857) 150 mg taken twice daily
Also known as: Selzentry
\[OBT (3-6 drugs based on treatment history and resistance testing)\]
\[OBT (3-6 drugs based on treatment history and resistance testing)\]
Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline
Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Time frame: Baseline
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Time frame: Baseline and Week 24
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Time frame: Baseline and Week 48
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
Time frame: Week 24 and 48
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline
Time frame: Week 24 and 48
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline
Time frame: Week 24 and 48
Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
Time frame: Week 24 and 48
Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline
Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
Time frame: Baseline
Change From Baseline in CD4 Cell Count at Week 24 and 48
Change from baseline in CD4 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
Time frame: Week 24 and 48
Change From Baseline in CD8 Cell Count at Week 24 and 48
Change from baseline in CD8 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
Time frame: Week 24 and 48
Time to Virological Failure
Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up\[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL (2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL (2 consecutive visits);failure if level \>=400 copies/mL (2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.
Time frame: Week 48
Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels
TAD from baseline was calculated as area under the curve of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as the average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Time frame: Baseline to Week 24 and Week 48
Number of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to protease inhibitors(PIs), nucleoside reverse transcriptase inhibitors(NRTIs) and non-nucleoside reverse transcriptase inhibitors(NNRTIs) were evaluated at screening (not at baseline), by Monogram Biosciences PhenoSense genotyping (GT) assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
Time frame: Screening
Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 24 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
Time frame: Screening and time of failure through Week 24
Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 48 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
Time frame: Screening and time of failure through Week 48
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24
Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/Mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 24 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as the last on treatment assessment.
Time frame: Baseline and time of failure through Week 24
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
Number of participants per tropism status R5, X4, DM, or NR/NP at baseline and time of failure analyzed through week 48 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as BLQ. The assessment for time of treatment failure was defined as the last on treatment assessment.
Time frame: Baseline and time of failure through Week 48
Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening
Association between baseline resistance and virological response was assessed as change in viral load by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility. Baseline value is the average of the values from screening, randomization and immediately pre-dose.
Time frame: Baseline, Week 24 and Week 48
| Milestone | Maraviroc QD, Double Blind | Maraviroc BID, Double Blind | Placebo, Double Blind | Maraviroc BID, Open Label | In Study-off Drug (ISOD), Open Label | Maraviroc BID, Observation Phase | In Study-off Drug (ISOD), Observation Phase |
|---|---|---|---|---|---|---|---|
| Started | 186 | 194 | 94 | 0 | 0 | 0 | 0 |
| Treated | 182 | 191 | 91 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 186 | 194 | 94 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 7 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 21 | 23 | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Participant defaulted | 16 | 11 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, not treated | 4 | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing at cut-off date | 128 | 137 | 57 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 7 | 8 | 7 | 0 | 0 | 0 | 0 |
| Milestone | Maraviroc QD, Double Blind | Maraviroc BID, Double Blind | Placebo, Double Blind | Maraviroc BID, Open Label | In Study-off Drug (ISOD), Open Label | Maraviroc BID, Observation Phase | In Study-off Drug (ISOD), Observation Phase |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 272 | 50 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 272 | 50 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 8 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant defaulted | 0 | 0 | 0 | 18 | 0 | 0 | 0 |
| Withdrew: Ongoing at cut-off date | 0 | 0 | 0 | 220 | 50 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 18 | 0 | 0 | 0 |
| Milestone | Maraviroc QD, Double Blind | Maraviroc BID, Double Blind | Placebo, Double Blind | Maraviroc BID, Open Label | In Study-off Drug (ISOD), Open Label | Maraviroc BID, Observation Phase | In Study-off Drug (ISOD), Observation Phase |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 205 | 65 |
| Completed | 0 | 0 | 0 | 0 | 0 | 160 | 48 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 45 | 17 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Participant defaulted | 0 | 0 | 0 | 0 | 0 | 17 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 21 | 10 |
Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
| log10 copies/milliliter(log10 copies/mL) | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline | 4.873 ± 0.6641 | 4.840 ± 0.6205 | 4.886 ± 0.6957 |
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
| log10 copies/mL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24 | -1.950 ± 0.1054 | -1.971 ± 0.1026 | -0.929 ± 0.1473 |
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
| log10 copies/mL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48 | -1.718 ± 0.1086 | -1.865 ± 0.1057 | -0.757 ± 0.1518 |
| percentage of participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 55.49 | 61.26 | 23.08 |
| Week 48 | 52.75 | 54.97 | 23.08 |
| percentage of participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 69.78 | 72.25 | 37.36 |
| Week 48 | 60.99 | 65.97 | 31.87 |
| percentage of participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 66.48 | 69.63 | 30.77 |
| Week 48 | 58.79 | 63.35 | 27.47 |
| percentage of participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 45.60 | 40.84 | 20.88 |
| Week 48 | 45.05 | 44.50 | 17.58 |
Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
| cells per microliter (cells/μL) | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| CD4 | 206.0 ± 171.99 | 204.9 ± 149.21 | 198.5 ± 140.39 |
| CD8 | 994.6 ± 658.03 | 996.9 ± 576.97 | 952.3 ± 598.19 |
Change from baseline in CD4 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
| cells/μL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 111.72 ± 7.821 | 101.89 ± 7.684 | 63.78 ± 10.929 |
| Week 48 | 121.49 ± 8.651 | 127.80 ± 8.499 | 69.34 ± 12.088 |
Change from baseline in CD8 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.
| cells/μL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | 340.74 ± 41.601 | 255.40 ± 40.873 | 122.18 ± 58.150 |
| Week 48 | 241.43 ± 33.789 | 244.75 ± 33.198 | 104.51 ± 47.231 |
Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up\[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL (2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL (2 consecutive visits);failure if level \>=400 copies/mL (2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.
| days | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Time to Virological Failure | 345.00 (197.00 to NA) | 361.00 (361.00 to NA) | 0.00 (NA to NA) |
TAD from baseline was calculated as area under the curve of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as the average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
| log10 copies/mL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24 | -1.748 ± 0.0897 | -1.755 ± 0.0873 | -0.872 ± 0.1254 |
| Week 48 | -1.603 ± 0.0994 | -1.781 ± 0.0968 | -0.748 ± 0.1390 |
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to protease inhibitors(PIs), nucleoside reverse transcriptase inhibitors(NRTIs) and non-nucleoside reverse transcriptase inhibitors(NNRTIs) were evaluated at screening (not at baseline), by Monogram Biosciences PhenoSense genotyping (GT) assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
| participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| GSS: 0 | 39 | 43 | 20 |
| GSS: 1 | 64 | 58 | 24 |
| GSS: 2 | 25 | 32 | 20 |
| GSS: greater than or equal to 3 | 52 | 57 | 25 |
| GSS: missing | 2 | 1 | 2 |
| PSS: 0 | 20 | 26 | 12 |
| PSS: 1 | 46 | 42 | 20 |
| PSS: 2 | 42 | 38 | 23 |
| PSS: greater than or equal to 3 | 71 | 84 | 34 |
| PSS: missing | 3 | 1 | 2 |
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 24 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
| participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Change in GSS by less than -3 (n= 22, 25, 40) | 0 | 1 | 0 |
| Change in GSS by -3 (n= 22, 25, 40) | 0 | 0 | 0 |
| Change in GSS by -2 (n= 22, 25, 40) | 0 | 0 | 1 |
| Change in GSS by -1 (n= 22, 25, 40) | 9 | 6 | 15 |
| Change in GSS by 0 (n= 22, 25, 40) | 13 | 15 | 22 |
| Change in GSS by 1 (n= 22, 25, 40) | 0 | 3 | 1 |
| Change in GSS by 2 (n= 22, 25, 40) | 0 | 0 | 1 |
| Change in GSS by 3 (n= 22, 25, 40) | 0 | 0 | 0 |
| Change in GSS by greater than 3 (n= 22, 25, 40) | 0 | 0 | 0 |
| Change in PSS by less than -3 (n= 22, 24, 40) | 0 | 0 | 0 |
| Change in PSS by -3 (n= 22, 24, 40) | 1 | 0 | 2 |
| Change in PSS by -2 (n= 22, 24, 40) | 2 | 3 | 3 |
| Change in PSS by -1 (n= 22, 24, 40) | 8 | 8 | 16 |
| Change in PSS by 0 (n= 22, 24, 40) | 10 | 13 | 18 |
| Change in PSS by 1 (n= 22, 24, 40) | 1 | 0 | 1 |
| Change in PSS by 2 (n= 22, 24, 40) | 0 | 0 | 0 |
| Change in PSS by 3 (n= 22, 24, 40) | 0 | 0 | 0 |
| Change in PSS by greater than 3 (n= 22, 24, 40) | 0 | 0 | 0 |
Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 48 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.
| participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Change in GSS by less than -3 (n= 35, 33, 46) | 0 | 1 | 0 |
| Change in GSS by -3 (n= 35, 33, 46) | 0 | 0 | 0 |
| Change in GSS by -2 (n= 35, 33, 46) | 0 | 0 | 2 |
| Change in GSS by -1 (n= 35, 33, 46) | 12 | 6 | 17 |
| Change in GSS by 0 (n= 35, 33, 46) | 23 | 22 | 24 |
| Change in GSS by 1 (n= 35, 33, 46) | 0 | 4 | 2 |
| Change in GSS by 2 (n= 35, 33, 46) | 0 | 0 | 1 |
| Change in GSS by 3 (n= 35, 33, 46) | 0 | 0 | 0 |
| Change in GSS by greater than 3 (n= 35, 33, 46) | 0 | 0 | 0 |
| Change in PSS by less than -3 (n= 35, 32, 46) | 0 | 0 | 0 |
| Change in PSS by -3 (n= 35, 32, 46) | 1 | 0 | 3 |
| Change in PSS by -2 (n= 35, 32, 46) | 3 | 3 | 4 |
| Change in PSS by -1 (n= 35, 32, 46) | 13 | 9 | 18 |
| Change in PSS by 0 (n= 35, 32, 46) | 16 | 19 | 19 |
| Change in PSS by 1 (n= 35, 32, 46) | 2 | 0 | 2 |
| Change in PSS by 2 (n= 35, 32, 46) | 0 | 1 | 0 |
| Change in PSS by 3 (n= 35, 32, 46) | 0 | 0 | 0 |
| Change in PSS by greater than 3 (n= 35, 32, 46) | 0 | 0 | 0 |
Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/Mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 24 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as the last on treatment assessment.
| participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Baseline: R5; Treatment failure: R5 | 8 | 7 | 36 |
| Baseline: R5; Treatment failure: X4 | 2 | 2 | 0 |
| Baseline: R5; Treatment failure: DM | 5 | 6 | 3 |
| Baseline: R5; Treatment failure: NR/NP | 6 | 5 | 2 |
| Baseline: DM; Treatment failure: R5 | 1 | 0 | 2 |
| Baseline: DM; Treatment failure: X4 | 0 | 2 | 0 |
| Baseline: DM; Treatment failure: DM | 3 | 7 | 0 |
| Baseline: DM; Treatment failure: NR/NP | 0 | 1 | 0 |
Number of participants per tropism status R5, X4, DM, or NR/NP at baseline and time of failure analyzed through week 48 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as BLQ. The assessment for time of treatment failure was defined as the last on treatment assessment.
| participants | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Baseline: R5; Treatment failure: R5 | 17 | 9 | 40 |
| Baseline: R5; Treatment failure: X4 | 2 | 2 | 0 |
| Baseline: R5; Treatment failure: DM | 8 | 10 | 3 |
| Baseline: R5; Treatment failure: NR/NP | 6 | 6 | 2 |
| Baseline: DM; Treatment failure: R5 | 1 | 0 | 3 |
| Baseline: DM; Treatment failure: X4 | 0 | 2 | 0 |
| Baseline: DM; Treatment failure: DM | 3 | 7 | 0 |
| Baseline: DM; Treatment failure: NR/NP | 0 | 1 | 0 |
Association between baseline resistance and virological response was assessed as change in viral load by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility. Baseline value is the average of the values from screening, randomization and immediately pre-dose.
| log10copies/mL | Maraviroc QD | Maraviroc BID | Placebo |
|---|---|---|---|
| Week 24; Screening OSS 0 (n= 22, 29, 16) | -1.721 ± 1.0477 | -1.231 ± 1.2924 | -0.264 ± 0.8979 |
| Week 24; Screening OSS 1 (n= 54, 48, 23) | -1.822 ± 1.0244 | -2.051 ± 1.1860 | -0.651 ± 0.9756 |
| Week 24; Screening OSS 2 (n= 37, 39, 21) | -2.145 ± 1.4052 | -2.515 ± 0.8209 | -0.611 ± 0.9732 |
| Week 24; Screening OSS >=3 (n= 64, 68, 29) | -2.655 ± 1.1364 | -2.530 ± 1.2694 | -2.109 ± 1.3495 |
| Week 24; Screening OSS= Missing (n= 3, 1, 2) | -2.642 ± 0.9282 | -0.544 ± NA | -1.169 ± 2.1350 |
| Week 48; Screening OSS 0 (n= 22, 29, 16) | -1.745 ± 1.2354 | -1.290 ± 1.2978 | -0.249 ± 0.8727 |
| Week 48; Screening OSS 1 (n= 54, 48, 23) | -1.678 ± 1.2115 | -1.899 ± 1.1966 | -0.594 ± 0.9454 |
| Week 48; Screening OSS 2 (n= 38, 39, 21) | -2.207 ± 1.3866 | -2.565 ± 0.8734 | -0.591 ± 0.9309 |
| Week 48; Screening OSS >=3 (n= 63, 68, 29) | -2.448 ± 1.2477 | -2.426 ± 1.2977 | -1.942 ± 1.4167 |
| Week 48; Screening OSS= Missing (n= 3, 1, 2) | -2.795 ± 0.5079 | -0.833 ± NA | -1.105 ± 2.0447 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc QD | — | 40/182 (22%) | 138/182 (75.8%) |
| Maraviroc BID | — | 46/191 (24.1%) | 147/191 (77%) |
| Placebo | — | 16/91 (17.6%) | 64/91 (70.3%) |
| Maraviroc BID, Open Label | — | 28/272 (10.3%) | 15/272 (5.5%) |
| In Study-off Drug, Open Label | — | 0/50 (0%) | 0/50 (0%) |
| Maraviroc BID, Observation Phase | — | 0/205 (0%) | 0/205 (0%) |
| In Study-off Drug, Observation Phase | — | 0/65 (0%) | 0/65 (0%) |
| Event | Maraviroc QD | Maraviroc BID | Placebo | Maraviroc BID, Open Label | In Study-off Drug, Open Label | Maraviroc BID, Observation Phase | In Study-off Drug, Observation Phase |
|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/182 | 2/191 | 3/91 | 1/272 | 0/50 | 0/205 | 0/65 |
| PneumoniaInfections and infestations | 2/182 | 5/191 | 1/91 | 3/272 | 0/50 | 0/205 | 0/65 |
| VomitingGastrointestinal disorders | 3/182 | 3/191 | 2/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Renal failure acuteRenal and urinary disorders | 1/182 | 1/191 | 2/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| NauseaGastrointestinal disorders | 3/182 | 2/191 | 1/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Aortic valve diseaseCardiac disorders | 0/182 | 0/191 | 1/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Supraventricular tachyarrhythmiaCardiac disorders | 0/182 | 0/191 | 1/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| DiarrhoeaGastrointestinal disorders | 2/182 | 2/191 | 1/91 | 1/272 | 0/50 | 0/205 | 0/65 |
| Drug hypersensitivityImmune system disorders | 1/182 | 1/191 | 1/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Anogenital wartsInfections and infestations | 2/182 | 0/191 | 0/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Event | Maraviroc QD | Maraviroc BID | Placebo | Maraviroc BID, Open Label | In Study-off Drug, Open Label | Maraviroc BID, Observation Phase | In Study-off Drug, Observation Phase |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 49/182 | 39/191 | 19/91 | 15/272 | 0/50 | 0/205 | 0/65 |
| NauseaGastrointestinal disorders | 39/182 | 33/191 | 17/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| HeadacheNervous system disorders | 36/182 | 30/191 | 16/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| NasopharyngitisInfections and infestations | 28/182 | 27/191 | 4/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/182 | 28/191 | 5/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| FatigueGeneral disorders | 25/182 | 22/191 | 13/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| PyrexiaGeneral disorders | 14/182 | 26/191 | 8/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Upper respiratory tract infectionInfections and infestations | 20/182 | 26/191 | 5/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| VomitingGastrointestinal disorders | 24/182 | 20/191 | 9/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| BronchitisInfections and infestations | 18/182 | 18/191 | 7/91 | 0/272 | 0/50 | 0/205 | 0/65 |
| Age, Customized(participants) | Maraviroc QD | Maraviroc BID | Placebo | Total |
|---|---|---|---|---|
| Less than 18 years | 1 | 0 | 0 | 1 |
| 18 to 24 years | 1 | 1 | 0 | 2 |
| 25 to 34 years | 8 | 9 | 6 | 23 |
| 35 to 44 years | 85 | 71 | 40 | 196 |
| 45 to 54 years | 63 | 70 | 32 | 165 |
| 55 to 64 years | 19 | 37 | 11 | 67 |
| Greater than or equal to 65 years | 5 | 3 | 2 | 10 |
| Sex: Female, Male(Participants) | Maraviroc QD | Maraviroc BID | Placebo | Total |
|---|---|---|---|---|
| Female | 29 | 21 | 12 | 62 |
| Male | 153 | 170 | 79 | 402 |
Showing the first 100 of 172 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2004, a primary completion of Apr 2007 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc